Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence

Cholera Clinical Trial

Official title:

Community-based Monitoring of Cholera Antibodies' Seroprevalence, and Home Follow-up of Positive Cases, in the Context of Cholera Vaccination Campaign, Democratic Republic of the Congo

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05829772
• Other study ID #: 2146-WT
• Status: Recruiting
• Start date: September 20, 2021
• Est. completion date: April 2024

Study information

• Verified date: May 2023
• Source: Epicentre
• Contact: Anais Broban
• Phone: +33140215429
• Email: anais.broban[@]epicentre.msf.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality

Description:

The project will comprise three different components: Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination. Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months). Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases. The present protocol relates to the setup of seroprevalence surveys and the follow up of individuals with positive V. cholerae shedding identified through seroprevalence surveys, in DRC. This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives: 1. To calculate the proportion of individuals infected with cholera recently (i.e. previous year or last 2 months) before the campaign distribution or in non-vaccinated zones (baseline survey, rural site) or following the mass OCV campaign and before the start of the usual cholera season (pre-season survey, urban site). 2. To assess proportion of individuals recently infected (i.e. infected in the last two months or in the last year) during the expected peak-week of cholera in the area (peak survey, urban site) and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey. 3. To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey) 4. To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination 5. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. 6. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 7000
• Est. completion date: April 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All persons,

1. Living in the randomly-selected households in targeted area AND

2. Randomly selected among household members. Inclusions will be limited to 1 participant per household, except for one survey AND

3. Giving his/her consent (or assent for children 13 to 17 years old) to participate in the study

Exclusion Criteria:

• People who decline to participate will be excluded from the study. For 2nd survey in Goma only: members of the household who cannot be reached after 2 attempts will be excluded.

Related Conditions & MeSH terms

• Cholera

Locations

Country	Name	City	State
Congo, The Democratic Republic of the	Epicentre/Médecins Sans Frontières	Bukama	Haut-Lomami
Congo, The Democratic Republic of the	Médecins Sans Frontières France	Goma	Nord Kivu

Sponsors (6)

Lead Sponsor	Collaborator
Epicentre	Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo, Institut Pasteur, Medecins Sans Frontieres, France, Ministry of Public Health, Democratic Republic of the Congo, Wellcome Trust

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To better characterize cholera immunization in the population of cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage	Cholera-specific antibody levels will be measured in all participants for each surveys. Serial surveys will allow monitoring level of antibodies over time following the vaccination campaign	2 years
Secondary	Calculate proportion of individuals infected with cholera (previous year or last 2 months) before the campaign distribution or in non-vaccinated zones or following the massOCV campaign and before the start of cholera season:pre-season survey, urban site.		2 years
Secondary	Assess proportion of individuals infected (the last 2 months or previous year) during the expected peak-week of cholera in the area and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey.		2years
Secondary	To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey)		2 years
Secondary	To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination		2 years
Secondary	To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment.		2 years
Secondary	To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.		2 years